bioMérieux – Third-Quarter 2020 Business Review22 October, 2020
- Organic growth of 19.4% at constant exchange rates and scope of consolidation over the first nine months of the year:
- €2,266 million in sales
- Up 17.5% as reported
- Further exceptional momentum in the third quarter driven by the molecular biology solutions, resulting in quarterly growth of 26.5%.
- Moderate year-on-year slowdown in immunoassays, clinical microbiology and industrial applications, however improving compared with the previous quarter.
- 2020 outlook: bioMérieux expects sales growth to be above 16% at constant exchange rates and scope of consolidation, and contributive operating income before non-recurring items to exceed €520 million.
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “Fighting the pandemic is a priority for bioMérieux. Our employees are fully engaged and we are mobilizing as much of our production, logistics and R&D resources as possible to fulfill our public health mission. bioMérieux performed exceptionally well in the third quarter, however recent pandemic-related developments and the associated lockdown measures require us to be cautious in our performance outlook. We can nonetheless confirm that, in 2020, we will deliver remarkable growth of consolidated sales and contributive operating income before non-recurring items. Even so, this performance is not projectable as such beyond 2020 ”